These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 3689664)

  • 1. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE; Rubens RD
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ; Bijvoet OL; van Oosterom AT
    Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
    Sleeboom HP; Bijvoet OL; van Oosterom AT; Gleed JH; O'Riordan JL
    Lancet; 1983 Jul; 2(8344):239-43. PubMed ID: 6135076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
    Grutters JC; Hermus AR; de Mulder PH; Beex LV
    Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
    Thiebaud D; Jaeger P; Burckhardt P
    J Bone Miner Res; 1990 Mar; 5(3):221-6. PubMed ID: 2333780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ; Borkowski A; Cleeren A; Bijvoet OL
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
    Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
    Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
    Yates AJ; Murray RM; Jerums GJ; Martin TJ
    Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
    Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
    Dodwell DJ; Howell A; Ford J
    Br J Cancer; 1990 Jan; 61(1):123-5. PubMed ID: 2297483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment.
    Gibbs CJ; Peacock M
    Postgrad Med J; 1986 Oct; 62(732):937-8. PubMed ID: 3774726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
    Davis JR; Heath DA
    Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
    Sawyer N; Newstead C; Drummond A; Cunningham J
    Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.